• Consensus Rating: Hold
  • Consensus Price Target: $16.00
  • Forecasted Upside: 20.48 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$13.28
▼ -0.43 (-3.14%)

This chart shows the closing price for HCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HUTCHMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

Analyst Price Target is $16.00
▲ +20.48% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for HUTCHMED in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 20.48% upside from the last price of $13.28.

This chart shows the closing price for HCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in HUTCHMED. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$14.00 ➝ $16.00Low
8/2/2022The Goldman Sachs GroupLower TargetNeutral$16.00 ➝ $14.00Low
5/4/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$46.00High
8/3/2021Jefferies Financial GroupInitiated CoverageBuy$52.00Low
7/13/2021Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $45.00Low
2/16/2021MizuhoInitiated CoverageBuyLow
10/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$40.00Medium
3/12/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
2/20/2020The Goldman Sachs GroupInitiated CoverageBuyLow
11/19/2019CLSAInitiated CoverageBuyLow
10/23/2019Bank of AmericaInitiated CoverageBuy$35.00 ➝ $29.00High
7/5/2019MacquarieInitiated CoverageOutperform ➝ OutperformLow
3/27/2019HSBCInitiated CoverageBuyLow
3/4/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$26.82Low
(Data available from 12/7/2017 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/10/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
HUTCHMED logo
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Read More

Today's Range

Now: $13.28
Low: $13.09
High: $13.49

50 Day Range

MA: $9.74
Low: $7.65
High: $13.71

52 Week Range

Now: $13.28
Low: $7.39
High: $36.29

Volume

660,399 shs

Average Volume

528,947 shs

Market Capitalization

$2.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of HUTCHMED?

The following Wall Street sell-side analysts have issued research reports on HUTCHMED in the last twelve months: Deutsche Bank Aktiengesellschaft, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for HCM.

What is the current price target for HUTCHMED?

1 Wall Street analysts have set twelve-month price targets for HUTCHMED in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 20.5%. The Goldman Sachs Group, Inc. has the highest price target set, predicting HCM will reach $16.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $16.00 for HUTCHMED in the next year.
View the latest price targets for HCM.

What is the current consensus analyst rating for HUTCHMED?

HUTCHMED currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HCM, but not buy more shares or sell existing shares.
View the latest ratings for HCM.

What other companies compete with HUTCHMED?

How do I contact HUTCHMED's investor relations team?

HUTCHMED's physical mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company's listed phone number is 852-2121-3888 and its investor relations email address is [email protected] The official website for HUTCHMED is www.chi-med.com. Learn More about contacing HUTCHMED investor relations.